Company Overview and News
VANCOUVER, British Columbia, May 17, 2018 (GLOBE NEWSWIRE) -- Affinor Growers Ltd. (“Affinor Growers”) (CSE:AFI) (OTC:RSSFF) (Frankfurt:1AF) is pleased to announce it has signed a definitive license agreement , with a later stage Licensed Producer Applicant in British Columbia. The license represents royalties of 3% of all products grown using the patented technology and gives the exclusive rights for Vancouver Island for Fruits, Vegetables and Marijuana once the Health Canada license is achieved, to grow, process, import and export Marijuana.
VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- AFFINOR GROWERS INC. (CSE:AFI) (OTCQB:RSSFF) (www.affinorgrowers.com) (the “Company”) is pleased to announce that the Company has appointed Randy Minhas, C.Dir, CPA, CA, BBA as the Company’s new Chief Financial Officer effective immediately. Mr. Minhas is a Chartered Professional Accountant with extensive finance experience in the technology, manufacturing and resources industries.
RPM ALO AFI RPMGD RPMGF RSSFF
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Vertical Designs Colombia Inc. SAS. (“Vertical Designs Colombia”) is a privately held whole owned subsidiary of Vertical Designs LTD based in Abbotsford BC Canada currently signed under a Letter Of Intent to enter the public markets with Bullion Gold on the TSX.V:BGD.
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Vertical Designs Colombia Inc. SAS. (“Vertical Designs Colombia”) is a privately held whole owned subsidiary of Vertical Designs LTD based in Abbotsford, BC, Canada currently signed under a Letter Of Intent to enter the public markets with Bullion Gold on the TSX.V.
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Affinor Growers Inc. (“Affinor Growers”) (CSE:AFI) (OTC:RSSFF) (Frankfurt:1AF) announces that it has closed the first tranche of the $0.11 per unit financing announced on April 10, 2018 at $352,400.
VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- Affinor Growers Inc. (“Affinor Growers”) (CSE:AFI) (OTC:RSSFF) (Frankfurt:1AF) announces that it has determined to not exercise its overallotment option previously announced on March 8, 2018. The private placement of units of Affinor Growers announced on March 5, 2018 has officially closed.
In a release issued yesterday by Affinor Growers, please note that the headline should read "Affinor Growers to Receive 10% of Vertical Designs Colombia", not "Affinor Growers to Receive 10% of Vertical Designs" as previously stated. The corrected release follows:
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- Vertical Designs Ltd. (“Vertical Designs”) is a privately held Agriculture Design Firm based in Abbotsford BC.
VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) -- Affinor Growers Ltd. (“Affinor Growers”) (CSE:AFI) (OTC:RSSFF) (Frankfurt:1AF) is pleased to announce that it has signed an exclusive manufacturing license with Cobotix Manufacturing Inc. (“Cobotix”) on March 26, 2018. Cobotix plans to incorporate in Aruba to build a state of the art manufacturing plant by the beginning of August 2018 to manufacture the patented stainless-steel towers for the Caribbean for mass production of fruits and vegetables.
9h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to CNSX:AFI / Affinor Growers, Inc. on message board site Silicon Investor.